Prostate Cancer | Specialty

Questions Loom Over Androgen-Targeting Strategies in Metastatic Prostate Cancer

March 22nd 2016

Targeting androgen receptor signaling with recently approved agents has improved outcomes for men with metastatic castration-resistant prostate cancer but significant questions linger about how to tackle resistance to the therapies.

Expert Says Radium-223 Emerged as “Surprise” Solution to Improving OS in mCRPC

March 22nd 2016

E. David Crawford, MD, discusses the history of radium-223 dichloride (Xofigo) and how it could be used in the future.

Dr. Dreicer on the Optimal Use of Radium-223 in Prostate Cancer

March 21st 2016

Robert Dreicer, MD, professor, Department of Medicine, Division of Hematology/Oncology, University of Virginia Health System, discusses the optimal use of radium-223 dichloride (Xofigo) for patients with metastatic castration-resistant prostate cancer.

Beyond PSA: What's Next for Prostate Cancer Detection?

March 17th 2016

Stacy Loeb, MD, discusses how screening tests for prostate cancer work, what their benefits are, and what urological specialists need to know in order to best utilize them.

Earlier Abiraterone More Effective for Chemo-Naïve mCRPC

March 14th 2016

Treatment with abiraterone acetate plus prednisone demonstrated an 11.8-month improvement in overall survival compared with prednisone and placebo for men with less advanced, chemotherapy-naïve metastatic castration-resistant prostate cancer.

Quality of Life Scores Similar in Men Undergoing Active Surveillance Versus Those Without Prostate Cancer

March 14th 2016

Men with low-risk prostate cancer who chose active surveillance (AS) reported a higher quality of life than men who chose direct active treatment such as surgery or radiation.

Secondary Cancers Linked to Radiotherapy in Men With Prostate Cancer

March 9th 2016

Men with prostate cancer treated with radiotherapy were at higher risk for developing second malignancies in the bladder, colon, and rectum compared with men who were not exposed to radiotherapy.

The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations

March 8th 2016

Researchers evaluate the role of magnetic resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.

Vitamin D Could Serve as Biomarker for Aggressive Prostate Cancer

March 7th 2016

The level of vitamin D in a patient’s blood could serve as a biomarker for an aggressive form of prostate cancer, especially in men who are considering active surveillance for the disease.

Personalized Therapy Emerging for Patients With Prostate Cancer

March 6th 2016

Tomasz M. Beer, MD, FACP, discusses how having a deeper understanding of the genetic makeup of patients with castration-resistant prostate cancer would open the door to novel treatments, both monotherapy and combination regimens.

Dr. Turkbey on Sodium Fluoride PET Imaging for Prostate Cancer

March 3rd 2016

Ismail Baris Turkbey, MD, staff clinician in the Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, discusses sodium fluoride PET imaging for patients with prostate cancer.

Biomarker-Directed Galeterone Explored in Prostate Cancer Trial

February 24th 2016

Galeterone is being explored in the ARMOR 3-SV study, in which men with progressive metastatic disease who have received prior androgen deprivation therapy are randomized to receive either galeterone or enzalutamide.

Evidence Supports Earlier Use of Radium-223, Expert Says

February 24th 2016

Fred Saad, MD, discusses treatment with radium-223 in asymptomatic patients and potential combination regimens with the radiopharmaceutical in castration-resistant prostate cancer.

With Radium-223 Leading the Way, Use of Radiopharmaceuticals Continues to Evolve

February 24th 2016

Neal Shore, MD, discusses the evolution of radiopharmaceuticals, how radium-223 works, and its potential for use in combination with other agents.

FDA Agrees to Review Supplemental NDA for Enzalutamide in Metastatic Prostate Cancer

February 23rd 2016

The FDA has accepted, for review, a supplemental new drug application for enzalutamide (Xtandi) capsules in patients with metastatic castration-resistant prostate cancer that includes findings from the head-to-head studies, TERRAIN and STRIVE.

Dr. Emberton on Focal Therapy Techniques in Prostate Cancer

February 23rd 2016

Mark Emberton, MD, professor of Interventional Oncology, Division of Surgery and Interventional Science, University College London Hospitals, clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, discusses techniques of focal therapy in patients with prostate cancer.

Dr. Saad on Expanded Access Program With Radium-223

February 23rd 2016

Fred Saad, MD, FRCSC, principal scientist, full professor, Department of Surgery, chair in Prostate Cancer Research, Université de Montréal, medical director, Interdisciplinary Urologic Oncology Group, head, Urologic Oncology, CHUM, discusses the expanded access program (EAP) of radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

FDA Approval in Liposarcoma, Breakthrough Designations in mCRPC and AML, and More

February 5th 2016

Innovation, Education Critical to Optimizing Early Detection in Prostate Cancer

February 3rd 2016

E. David Crawford, MD, discusses his view of the current role for PSA testing in prostate cancer and the need for continued innovation and advancement with new screening technologies.

In a Crowded Field, High-Intensity Focused Ultrasound Stakes a Claim

February 2nd 2016

The landscape for the patient with localized prostate cancer is filled with both new and exciting treatments. With better methods to screen, improved imaging scans to determine physical location and extent of cancer, and even active surveillance, there are many options to consider.